Quoin raises up to $50M to push rare-disease drug toward the finish line
What's the deal? Quoin PharmaceuticalsDealroom has a profile for this one. Try Dealroom → (NASDAQ: QNRX), a late clinical-stage specialty drugmaker focused on rare and orphan diseases, has entered a securities purchase agreement to raise up to $50 million in gross proceeds. The private placement includes about $30.8 million in upfront funding, plus up to $19.2 million if investors exercise accompanying warrants.
Backers include Sirenia Capital ManagementDealroom has a profile for this one. Try Dealroom →, Sphera Healthcare, AIGH Capital ManagementDealroom has a profile for this one. Try Dealroom →, Nantahala CapitalDealroom has a profile for this one. Try Dealroom →, StemPoint CapitalDealroom has a profile for this one. Try Dealroom →, and Stonepine Capital ManagementDealroom has a profile for this one. Try Dealroom →, along with members of Quoin's management and board.
Why now? The warrants expire on the earlier of five years from closing or 30 days after Quoin announces that its trial CL-QRX003-004 has met its primary endpoint. That trial evaluates QRX003 as a treatment for Netherton Syndrome, a rare genetic skin condition — tying the financing directly to a clinical milestone.
What's the endgame? Quoin plans to use the upfront proceeds for general corporate purposes, including completing clinical development of QRX003. Assuming all warrants are exercised in cash, the company expects the money to fund it into the second half of 2029.
The details: Quoin will issue 6,305,300 American Depositary Shares — or pre-funded warrants in lieu — plus warrants to buy up to 3,152,650 more ADSs. The placement is expected to close on or about August 31, 2026. Leerink PartnersDealroom has a profile for this one. Try Dealroom → is lead placement agent, with BTIGDealroom has a profile for this one. Try Dealroom → and Lake Street Capital MarketsDealroom has a profile for this one. Try Dealroom → as co-placement agents.
The signal: At $50 million, the deal ranks in the 93rd percentile of non-VC private placements over the past four years — a sizeable raise for a small-cap biotech betting on a single late-stage asset.
Image credit: Quoin Pharmaceuticals
